Harrow, Inc. (NASDAQ:HROW) Given Consensus Rating of “Moderate Buy” by Analysts

Harrow, Inc. (NASDAQ:HROW) has been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $69.4286.

Several equities analysts have weighed in on the company. B. Riley Financial restated a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. Weiss Ratings lowered Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Nomura downgraded Harrow to a “neutral” rating in a report on Wednesday, March 18th. Cantor Fitzgerald dropped their price target on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Harrow in a research report on Thursday, March 19th.

Insider Transactions at Harrow

In other Harrow news, CFO Andrew R. Boll acquired 3,500 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were acquired at an average cost of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the purchase, the chief financial officer owned 814,679 shares of the company’s stock, valued at approximately $24,358,902.10. This trade represents a 0.43% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Adrienne L. Graves acquired 1,000 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was acquired at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the purchase, the director directly owned 1,000 shares of the company’s stock, valued at $31,070. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On Harrow

A number of institutional investors have recently made changes to their positions in the business. Militia Capital Management LLC bought a new position in shares of Harrow in the first quarter worth about $829,000. California State Teachers Retirement System increased its stake in Harrow by 26.6% during the first quarter. California State Teachers Retirement System now owns 39,019 shares of the company’s stock valued at $1,376,000 after acquiring an additional 8,198 shares during the period. Quantinno Capital Management LP increased its stake in Harrow by 34.1% during the first quarter. Quantinno Capital Management LP now owns 7,199 shares of the company’s stock valued at $254,000 after acquiring an additional 1,829 shares during the period. Corsair Capital Management L.P. increased its stake in Harrow by 90.0% during the first quarter. Corsair Capital Management L.P. now owns 19,000 shares of the company’s stock valued at $670,000 after acquiring an additional 9,000 shares during the period. Finally, Luxor Capital Group LP increased its stake in Harrow by 22.0% during the first quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock valued at $39,470,000 after acquiring an additional 201,859 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $42.87 on Monday. The business’s 50-day moving average price is $36.56 and its two-hundred day moving average price is $41.64. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. Harrow has a one year low of $28.54 and a one year high of $54.85. The company has a market capitalization of $1.60 billion, a P/E ratio of -104.56 and a beta of 0.28.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. During the same quarter last year, the firm earned ($0.38) EPS. Analysts anticipate that Harrow will post 0.29 earnings per share for the current fiscal year.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.